SERENA-6 interpretation and clinical implications: intercepting endocrine resistance in metastatic breast cancer

npj Breast Cancer 2026 Open access

Read full text
Authors: Francois Clement Bidard, Carlos Barrios, Giampaolo Bianchini, Adam Brufsky, Stephen Chia, Javier Cortes, Massimo Cristofanilli, Giuseppe Curigliano, Shaheenah Dawood, Peter A. Fasching, Lorenzo Gerratana, A G Giordano
+20 more Michail Ignatiadis, Hiroji Iwata, Wolfgang Janni, Elgene Lim, Kevin Kalinsky, Cynthia X. Ma, Erica L. Mayer, Arielle J. Medford, Jason Aboudi Mouabbi, Joyce O’Shaughnessy, Yeon Hee Park, Javier Pascual, Pedram Razavi, Sarah Sammons, José Luis Sandoval, Luisana Sisca, Paolo Tarantino, Seth A. Wander, Gustavo Werutsky, Nicholas Turner
DOI: 10.1038/s41523-026-00967-4
Cited by: 1
References: 22

Abstract

In patients treated with first-line AI plus CDK4/6 inhibitor, SERENA-6 showed the benefit of switching from an aromatase inhibitor to the oral SERD camizestrant upon detection of an emerging ESR1 mutation, before disease progression. While this adaptive oncology approach has shown key benefits for patients, the integration of emerging ctDNA targets into treatment decisions has been questioned. Here, we provide further clarification on several aspects of this clinically relevant discussion.

Fields of Study & Subjects

Advanced Breast Cancer Therapies Estrogen and related hormone effects Prostate Cancer Treatment and Research

Publication details

Journal / source
npj Breast Cancer
Publisher
Springer Science and Business Media LLC
Volume
12
Issue
1
Publication date
8 June 2026
Language
EN